Cover Image
市場調查報告書

化療誘發性噁心和嘔吐 (CINV) 治療藥的全球市場 (2015∼2019年)

Global Chemotheraphy Induced Nausea and Vomiting (CINV) Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 336912
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
化療誘發性噁心和嘔吐 (CINV) 治療藥的全球市場 (2015∼2019年) Global Chemotheraphy Induced Nausea and Vomiting (CINV) Drugs Market 2015-2019
出版日期: 2015年08月05日 內容資訊: 英文 73 Pages
簡介

所謂化療誘發性噁心和嘔吐 (CINV) ,是化療的副作用中尤其特別嚴重的。依據場合不同,也有即使是化療可治癒的癌症,也不得不延期、拒絕治療。還有化療伴隨的噁心和嘔吐也明顯降低患者的QoL (生活品質) 。成為CINV的神經傳達物質,有多巴胺和5-HT3、物質P、內源性大麻素等。CINV由於腹部的向心性迷走神經的嘔吐中樞受刺激,及最後區的CTZ (化學感受器觸發區) 受直接刺激而發作。根據CINV的種類,進行各種治療方法處方。CINV的治療使用的藥物類別中,有5-HT3受體拮抗劑和NK15-HT3受體拮抗劑、皮質類固醇、多巴胺拮抗劑、苯二氮平類藥物,大麻素等。目前所使用的治療藥大半有助於防止嘔吐,不過,噁心的治療效果有限。全球化療誘發性噁心和嘔吐 (CINV) 治療藥市場2014∼2019年預計以4.9%的年複合成長率(CAGR) 成長。

本報告提供全球化療誘發性噁心和嘔吐 (CINV) 治療藥的市場相關分析、疾病概要和市場基本結構、市場規模趨勢 (今後5年的預測值)、藥物的各給藥途徑、各類藥物、各治療法及疾病的各表現時期的詳細趨勢、地區市場結構、趨勢與管理體制、推動、阻礙市場要素與其影響力、主要企業、產品簡介、今後的市場機會等調查評估。

第1章 摘要整理

  • 分析結果的概要

第2章 分析範圍

  • 分析概要
  • 大供應商的主要產品

第3章 市場分析技術

  • 分析方法
  • 經濟指標

第4章 簡介

  • 市場趨勢的概要

第5章 產品簡介

  • Zofran
  • Aloxi/Onicit/Paloxi
  • Akynzeo
  • Emend

第6章 疾病概要

  • 對疾病的理解
  • 病理處理
  • CINV的種類
  • 原因
  • 風險要素
  • 管理
  • 經濟負擔

第7章 CINV相關的法規指南

第8章 開發平台分析

第9章 市場環境

  • 市場概要
  • 市場規模與其預測
  • 美國的CINV治療藥市場
  • 波特的五力分析

第10章 給藥途徑 (ROA) 各的市場區隔

  • 口服藥
  • 非口服藥
  • 經皮吸收貼片

第11章 CINV的各表現時期的市場區隔

  • 急性CINV
  • 延遲性CINV
  • 預測性CINV
  • 突出性CINV

第12章 治療藥的各藥理學性等級的市場區隔

  • 5-HT3受體拮抗劑
  • NK-1受體拮抗劑
  • 皮質類固醇
  • 多巴胺受體拮抗劑
  • 苯二氮平類藥物
  • 大麻素

第13章 治療方法的各種類的市場區隔

  • 單劑療法
  • 聯合治療

第14章 地區區分

第15章 市場成長的推動要素

第16章 推動因素與其影響力

第17章 市場課題

第18章 推動因素、課題的影響力

第19章 市場趨勢

第20章 供應商環境

  • 競爭方案
  • 市場佔有率分析
  • 其他卓越供應商

第21章 主要供應商分析

  • GlaxoSmithKline
  • Helsinn
  • Heron
  • Merck & Co. Inc.
  • Tesaro

第22章 附錄

  • 簡稱集

圖表一覽

目錄
Product Code: IRTNTR6836

About CINV

CINV is one of the most dreaded adverse effects of chemotherapy. It often leads to the postponement or refusal of potentially curative chemotherapy treatment for cancer. This nausea and vomiting, associated with chemotherapy regimen, affects the quality of life of an individual.

The neurotransmitters in CINV are dopamine, 5-HT3, substance P, and endocannabinoids. CINV can be caused by the stimulation of vomiting center by the abdominal vagal afferents or by the direct stimulation of CTZ in the area postrema. The risk of development of CINV changes with the use of different types of chemotherapy regimens such as high, moderate, low, and minimal risk.

Based on the type of CINV, different treatment regimens are prescribed. The classes of drugs used in the treatment of CINV are 5-HT3 receptor antagonists, NK1 receptor antagonists, corticosteroids, dopamine antagonists, benzodiazepines, and cannabinoids. Most of the drugs used in the treatment are helpful in the prevention of vomiting but show less effect in treating nausea.

Technavio's analysts forecast the global chemotherapy induced nausea and vomiting drugs market to grow at a CAGR of 4.9% over the period 2014-2019.

Covered in this report

The report covers the present scenario and the growth prospects of the global CINV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various branded therapies and generics along with the drugs used as off-label for the treatment of CINV.

Technavio's report, Global CINV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global CINV drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • GlaxoSmithKline
  • Helsinn
  • Heron Therapeutics
  • Merck & Co
  • Tesaro

Other Prominent Vendors

  • Acacia Pharma
  • Aphios
  • Barr Laboratories
  • Baxter Healthcare
  • Eisai
  • Especificos Stendhal
  • F.Hoffmann La Roche
  • Mundipharma
  • Mylan Pharmaceuticals
  • OPKO Health
  • Orchid Healthcare
  • Otsuka Pharmaceutical
  • ProStrakan
  • Sandoz (Novartis)
  • Solvay Pharmaceuticals
  • Specialised Therapeutics Australia
  • Sun Pharma
  • Taiho Pharmaceutical
  • Teva Pharmaceuticals

Market driver

  • Increase in incidence and prevalence of cancer
  • For a full, detailed list, view our report

Market challenge

  • Complex physiology of CINV
  • For a full, detailed list, view our report

Market trend

  • Increased use of combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Product profiles

  • Zofran
  • Aloxi/Onicit/Paloxi
  • Akynzeo
  • Emend

PART 06: Disease Overview

  • Understanding the disease
  • Pathophysiology
  • Types of CINV
  • Causes
  • Risk factors
  • Management
  • Economic burden

PART 07: Regulatory guidelines on CINV

PART 08: Pipeline analysis

PART 09: Market landscape

  • Market overview
  • Market size and forecast
  • CINV Drugs Market in US
  • Five forces analysis

PART 10: Market segmentation by ROA

  • Oral
  • Parenteral
  • Transdermal patch

PART 11: Market segmentation by onset of disease in CINV

  • Acute CINV
  • Delayed CINV
  • Anticipatory CINV
  • Breakthrough CINV

PART 12: Market segmentation by pharmacological class of drugs

  • 5-HT3 Receptor Antagonists
  • NK-1 Receptor Antagonists
  • Corticosteroids
  • Dopamine Receptor Antagonists
  • Benzodiazepines
  • Cannabinoids

PART 13: Market segmentation by type of therapy

  • Monotherapy
  • Combination therapy

PART 14: Geographical segmentation

PART 15: Market drivers

PART 16: Impact of drivers

PART 17: Market challenges

PART 18: Impact of drivers and challenges

PART 19: Market trends

PART 20: Vendor landscape

  • Competitive Scenario
  • Market Share Analysis 2014
  • Other prominent vendors

PART 21: Key vendor analysis

  • GlaxoSmithKline
  • Helsinn
  • Heron
  • Merck & Co. Inc.
  • Tesaro

PART 22: Appendix

  • List of abbreviation

List of Exhibits:

  • Exhibit 01: Product offerings
  • Exhibit 02: Types of CINV
  • Exhibit 03: Causes of emesis
  • Exhibit 04: Chemotherapeutic agents related emetic risk
  • Exhibit 05: Management of CINV
  • Exhibit 06: Summary of regulatory guidelines by ASCO, ESMO, MASCC, and NCCN for CINV treatment
  • Exhibit 07: Global CINV drugs market: Pipeline portfolio
  • Exhibit 08: Global CINV drugs market 2014-2019 ($ millions)
  • Exhibit 09: CINV drugs market in US 2014-2019 ($ millions)
  • Exhibit 10: Five forces analysis
  • Exhibit 11: Segmentation of global CINV drugs market by ROA
  • Exhibit 12: Global CINV drugs market segment by onset of disease
  • Exhibit 13: Global CINV drugs market segment by pharmacological class of drugs
  • Exhibit 14: Global CINV drugs market segment by type of therapy
  • Exhibit 15: Segmentation of Global CINV Drugs Market by Geography 2014
  • Exhibit 16: Drivers of global CINV drugs market
  • Exhibit 17: Impact of drivers
  • Exhibit 18: Challenges of global CINV drugs market
  • Exhibit 19: Impact of drivers and challenges
  • Exhibit 20: YoY growth and revenue of Emend 2011-2014 ($ millions)
  • Exhibit 21: GlaxoSmithKline: Business segmentation by revenue 2014
  • Exhibit 22: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 23: GlaxoSmithKline: Geographical segmentation by revenue 2014
  • Exhibit 24: Helsinn: products
  • Exhibit 25: Helsinn: Key pipeline products
  • Exhibit 26: Helsinn: Geographical presence
  • Exhibit 27: Heron: Product Pipeline
  • Exhibit 28: Merck & Co. Inc.: Business segmentation by revenue 2013
  • Exhibit 29: Merck & Co. Inc.: Business segmentation by revenue 2012 and 2013 (US$ billions)
  • Exhibit 30: Merck & Co. Inc.: Sales by geography 2013
  • Exhibit 31: Tesaro : Product segmentation
  • Exhibit 32: Tesaro : Geographical presence
Back to Top